Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.
Dr. Yogambha Ramaswamy is a Senior Lecturer in the School of Biomedical Engineering at The University of Sydney and a member of the Sydney Nano Institute. She holds a Master’s in Biotechnology from the University of Queensland and a PhD in Biomedical Engineering from the University of Sydney (2009). Her postdoctoral career began as a Vice-Chancellor’s Postdoctoral Research Fellow at the University of New South Wales, followed by a Peter Doherty Early Career Fellowship in 2013 before joining the University of Sydney in 2015. Dr. Ramaswamy’s research focuses on biomaterials, tissue engineering, and mechanobiology, with a particular emphasis on developing calcium silicate-based ceramics and biopolymers for orthopedic and regenerative applications. Her recent work explores the role of physical cues in modulating stem and cancer cell behavior. She teaches courses such as AMME1961 (Introduction to Biomedical Engineering B) and AMME5962 (Introduction to Mechanobiology). Her research has been supported by grants including the NHMRC Early Career Fellowship and collaborations with institutions like the CSIR-Indian Institute of Chemical Technology and the University of Otago. Her publications span biomaterials, nanotechnology, and mechanobiology, with recent work addressing atherosclerosis, hydrogel design, and nanomedicine. She currently supervises PhD students Frank (biomaterials) and Alexander (atherosclerosis research).
Anu Ramaswami is the Sanjay Swani ’87 Professor of India Studies and Professor of Civil and Environmental Engineering at Princeton, directing the M.S. Chadha Center. She leads research on sustainable, equitable urban systems, integrating infrastructure, food, energy, and water policies. Her work employs nexus modeling to co-produce decarbonization pathways with global cities, emphasizing health, equity, and resilience co-benefits. Recent projects analyze fine-scale urban metabolism and heat vulnerability in India. Awards include the AAEES Science Award (2022) for interdisciplinary impact. She chairs the Urban Nexus Lab, advancing data-driven urban transitions.
Bradley Nelson is a Full Professor of Robotics and Intelligent Systems at ETH Zürich since 2002, leading the Institute for Robotics and Intelligent Systems. He holds a Ph.D. in Robotics from Carnegie Mellon University (1995), with prior roles as Assistant Professor at the University of Illinois at Chicago (1995-1998) and Associate Professor at the University of Minnesota (1998-2002). His research focuses on microrobotics and nanorobotics for biomedical applications, including targeted drug delivery and medical robotics. He leads the Microrobotics Lab (MSRL) and chairs international workshops/conferences. Awards include IEEE and ASME Fellowships, and Best Paper accolades at major robotics venues. Research interests emphasize magnetic microrobot navigation, smart materials, and clinical translation of robotic systems. His work bridges engineering and medicine, addressing challenges like cerebral vasculature navigation for drug delivery. He has developed electromagnetically controllable catheters and telesurgery frameworks. Leadership roles include Head of the ETH Department of Mechanical and Process Engineering and Chairman of the ETH Electron Microscopy Center (EMEZ). Notable contributions include magnetically guided microcatheters, variable-stiffness catheters, and clinical-ready navigation systems. Ongoing projects explore magnetoelectric effects and biodegradable micromotors for environmental and biomedical uses. His lab collaborates with industry and academic partners globally to advance robotic solutions for healthcare challenges.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Dr. Yayun Du is an Assistant Professor in the Department of Electrical and Computer Engineering at Vanderbilt University School of Engineering. She holds a Ph.D. in Robotics and System Control (Minor: Solid Mechanics) from UCLA (2022) and was a postdoctoral scholar at Northwestern University's Rogers Group through 2024. Current faculty at Vanderbilt University Ph.D. from University of California, Los Angeles Postdoctoral experience at Northwestern University Her research integrates bioelectronics and robotics through three core directions: 1) Developing multimodal wearable/implantable sensors for health monitoring, 2) Creating human-in-the-loop interaction systems using brain-computer interfaces, and 3) Applying machine learning to medical environment robotics. She has deployed four sensor types across seven hospitals globally, serving users from neonates to elderly patients. Dr. Du's recent publications focus on wireless bioelectronic devices ( PNAS ), sustainable sensor materials ( ACS Sustainable Chemistry & Engineering ), and agricultural robotics ( ICRA , IROS ). She serves as Associate Editor for ICRA 2025 and has received two Best Paper Award final nominations at IROS 2021. Finalist - Best Paper Award in Agri-Robotics (IROS 2021) Finalist - Best Paper Award in Robot Mechanisms and Design (IROS 2021) As head of the Du Group, she leads interdisciplinary research with applications in both healthcare and agricultural contexts, collaborating with Vanderbilt Institute for Surgery and Engineering (VISE) and clinical partners. Her work emphasizes deployable systems that transition from academic research to real-world implementation in medical and industrial environments.
Jeremy Dahl is a Professor of Radiology (Pediatric Radiology) at Stanford University School of Medicine. He directs the Ultrasound Imaging & Instrumentation Lab and serves as Director of Research Academic Affairs in the Department of Radiology since 2020. He holds multiple affiliations across Stanford including Bio-X, the Cardiovascular Institute, Wu Tsai Human Performance Alliance, Maternal & Child Health Research Institute, Stanford Cancer Institute, and Wu Tsai Neurosciences Institute. Dr. Dahl received his B.S. in Electrical Engineering from the University of Cincinnati (1999) and Ph.D. in Biomedical Engineering from Duke University (2004). His research focuses on developing ultrasonic beamforming and image reconstruction methods for diagnostic imaging applications, particularly techniques that generate high-quality images in difficult-to-image patients. His laboratory specializes in B-mode and Doppler imaging techniques that utilize additional information from ultrasonic wavefields to improve image quality and develop real-time imaging systems for clinical applications including cardiac, liver, and fetal imaging. Dr. Dahl's research has led to significant advancements in ultrasound molecular imaging platforms, sound speed estimation, aberration correction, and reverberation noise suppression. His work often bridges engineering innovation with clinical applications for cancer detection and other diseases. His recent publications demonstrate strong focus on machine learning applications in ultrasound, distributed aberration correction, and molecular imaging techniques. Fellow, American Institute of Ultrasound in Medicine (2021) Senior Member, Institute of Electrical and Electronics Engineers (2020) Distinguished Investigator Award, The Academy for Radiology & Biomedical Imaging Research (2018) Outstanding Paper Award, IEEE Ultrasonics, Ferroelectrics, and Frequency Control Society (2011) Dr. Dahl serves in editorial roles for major journals including IEEE Transactions on Medical Imaging (2017-2024) and IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control (2013-Present). His laboratory has successfully translated numerous innovations into clinical applications, with multiple patents including recent developments in pulsed focused ultrasound therapy and speed of sound quantification.
Dr. Jose Perdomo is a Research Fellow at the Central Clinical School, Sydney Medical School, within the Faculty of Medicine and Health at the University of Sydney. He is based at the Charles Perkins Centre, where his research focuses on endothelial damage, immune complex-driven thrombosis, and platelet formation mechanisms. His work employs techniques such as flow cytometry, microfluidics, and intravital microscopy. Dr. Perdomo holds a PhD from the University of Sydney’s School of Molecular and Microbial Biosciences and received a Vice-Chancellor’s Fellowship. His research has led to two international patents and recognition, including 1st prize in the 2020 China Shenzhen Innovation Competition. His studies explore targeted inhibitors to prevent immune complex formation and thrombosis, with applications in cardiovascular health. His research interests include the interplay between white blood cells, endothelial cells, and platelets, with a focus on desialylation, apoptosis, and NETosis in immune thrombocytopenia. He has contributed to understanding vaccine-induced immune thrombocytopenia and thrombotic complications post-myocardial infarction. His findings have been featured in Nature Communications , Blood Advances , and other high-impact journals. Awards: 1st prize in China Shenzhen Innovation Competition (2020). Labs/Teams: Charles Perkins Centre, University of Sydney. Grants: Vice-Chancellor’s Fellowship (University of Sydney). Media Contributions: Insights into AstraZeneca vaccine-related blood clots featured in The Guardian , SMH , and ABC News.
Professor Robert McLaughlin is a faculty member in the School of Biomedicine at the University of Adelaide, affiliated with the Faculty of Health and Medical Sciences. He leads the Bioengineering Imaging Group and serves as Managing Director of the start-up Miniprobes. His research focuses on developing optical imaging technologies, including non-invasive tools for blood flow assessment and miniaturized imaging probes. He has secured over $14M in research grants and holds an h-index of 45 with 98 journal papers, 7 patents, and 2 book chapters. Prof. McLaughlin’s career includes roles at the University of Oxford and Siemens Medical Solutions, followed by academic leadership since 2007. His innovations span optical coherence tomography (OCT), fluorescence imaging, and dual-modality systems for clinical applications. Awards include the 2014 WA Innovator of the Year, 2015 Australian Innovation Challenge, and 2016 South Australian Premier’s Research Fellowship. His research emphasizes practical medical solutions, such as imaging needles for deep-tissue diagnostics and optical devices for real-time surgical monitoring. The Bioengineering Imaging Group collaborates with industry and academia to translate technologies into clinical practice.
David J Mehlman, MD serves as an Associate Professor in the Department of Medicine (Cardiology) at Northwestern University's Feinberg School of Medicine, with clinical practice at Northwestern Memorial Hospital. His expertise spans echocardiography, general cardiology, and prosthetic heart valve disease management. His academic training includes: MD from Johns Hopkins University (1973) Internal Medicine Intern at Johns Hopkins Hospital (1974) Medicine Resident at Johns Hopkins Hospital (1976) Cardiology Fellowship at University of Chicago Hospitals (1978) Dr. Mehlman's research focuses on structural heart disease mechanisms and diagnostic applications, particularly in valve prostheses evaluation and exercise-induced cardiac adaptations. His work bridges clinical cardiology with cardiovascular imaging techniques to address complications in valvular interventions and transplant-related cardiomyopathies. His publication history reveals consistent contributions to cardiovascular pathology, with emphasis on aortic homograft performance, amyloidosis-related cardiac deterioration, and athlete physiology. Key methodologies involve advanced echocardiography and radiofrequency ultrasound for prosthetic valve assessment. He maintains prestigious recognition as a Castle Connolly Top Doctor across multiple years: Castle Connolly Top Doctor (2019) Castle Connolly Top Doctor (2018) Castle Connolly Top Doctor (2017) Castle Connolly Top Doctor (2016) Castle Connolly Medical Top Doctor (2006) Castle Connolly Medical Top Doctor (2005) Castle Connolly Medical Top Doctor (2005) Castle Connolly Medical Top Doctor (2004) Board certified in Internal Medicine and Cardiovascular Disease by the American Board of Internal Medicine, Dr. Mehlman integrates clinical practice with ongoing research in structural heart disease while adhering to Northwestern's professional disclosure standards.
Nabil Alshurafa is an Associate Professor at Northwestern University, holding joint appointments in the McCormick School of Engineering (Computer Science and Electrical and Computer Engineering) and the Feinberg School of Medicine (Preventive Medicine). He directs the HABits Lab, which focuses on developing mHealth systems to address health behaviors such as overeating, stress, and UV exposure. His work integrates wearable sensors, machine learning, and behavioral science to create passive sensing solutions. Education: PhD in Computer Science and Wireless Health (UCLA), MS and BS in Computer Science (UCLA). Research Interests: Body sensor networks, activity recognition, embedded systems, and health informatics. His lab designs wearable devices (e.g., neck-worn sensors, UV patches) and AI frameworks to detect behaviors like eating patterns and stress levels. Collaborations include domain experts in medicine and engineering to translate technical innovations into clinical interventions. Recent Projects: Developing systems for stress monitoring via ECG-PPG patches, UV exposure tracking, and just-in-time interventions for overeating. The lab emphasizes ethical design, privacy preservation, and user-centered technology. Students and Lab Team: Supervises PhD, MS, and undergraduate researchers in areas like machine learning, embedded systems, and health data analytics. Notable advisees include Rawan Alharbi (PhD candidate), Shibo Zhang (PhD student), and Wilson Wang (MS student). Labs/Teams: HABits Lab collaborates with experts in Preventive Medicine, Psychiatry, and Dermatology to advance interdisciplinary health research. Current projects include predictive analytics for weight loss and interventions targeting maternal stress during pregnancy.
Associate Professor Anna Waterhouse is a Robinson Fellow and Head of the Cardiovascular Medical Devices Group at the Charles Perkins Centre, School of Medical Sciences, University of Sydney. Her research focuses on developing antithrombogenic materials and bioinspired medical devices to address cardiovascular diseases. She holds affiliations with the University of Sydney Nano Institute and the Australiasian Society for Biomaterials and Tissue Engineering as Treasurer and Secretary. Education includes a BSc (1st class hons) in Cell Biology from the University of Manchester and a PhD in bioengineering from the University of Sydney. She completed postdoctoral training at Harvard University’s Wyss Institute. Research interests span biomaterials, thrombosis prevention, and medical device engineering. Key projects include liquid-infused surfaces for anti-thrombotic coatings and biomimetic in vitro models. Her work integrates bioengineering, nanotechnology, and surface modification to improve medical device compatibility. Scientific awards include the Robinson Fellowship and CPC Mid-Career Researcher Support Award. Grants funded by ARC, Heart Foundation, and NSW Health support projects like slippery nano-coatings for medical devices. She advises PhD students in biomolecular nanotechnology, endothelial cell studies, and DNA nanostructures. Labs and collaborations involve Sydney Nano Institute and Charles Perkins Centre, focusing on translational research in cardiovascular and biomedical engineering.
